Detail akcie Bioporto online

Business Summary: Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, BioPorto A/S revenues increased 11% to DKR40.3M. Net loss increased 20% to DKR82.1M. Revenues reflect North America segment increase of 17% to DKR24.2M, Europe segment increase of 19% to DKR12.2M. Higher net loss reflects Other R & D increase from DKR14.2M to DKR32M (expense), Staff costs increase of 55% to DKR27.7M (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -DKR0.17.